A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
Exosome miR-30a-5p Regulates Glomerular Endothelial Cells' EndMT and Angiogenesis by Modulating Notch1/VEGF Signaling Pathway
CONCLUSION: This study provides evidence that exosome miR-30a-5p suppresses EndMT and abnormal angiogenesis of GECs by modulating the Notch1/VEGF signaling pathway. These findings suggest that exosome miR-30a-5p could be a potential therapeutic strategy for the treatment of DN.PMID:37767799 | DOI:10.2174/0115665232258527230919071328 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Yaxian Ning Xiaochun Zhou Gouqin Wang Lili Zhang Jianqin Wang Source Type: research
A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer
CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research
MicroRNA Theranostics in Cancer
Curr Gene Ther. 2023;23(5):329. doi: 10.2174/156652322305230808102847.NO ABSTRACTPMID:37728083 | DOI:10.2174/156652322305230808102847 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Sujay Paul Source Type: research
Exosomal miRNAs as Next-generation Therapy Vehicles in Breast Cancer
Curr Gene Ther. 2023;23(5):330-342. doi: 10.2174/1566523223666230215103524.ABSTRACTThe second most pervasive cancer affecting the survival of women across the world is breast cancer. One of the biggest challenges in breast cancer treatment is the chemoresistance of cancer cells to various medications after some time. Therefore, highly specific blood-based biomarkers are required for early breast cancer diagnosis to overcome chemoresistance and improve patient survival. These days, exosomal miRNAs have attracted much attention as early diagnostic blood-based biomarkers because of their high stability, secretion from maligna...
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Priyanka Thakur Harshita Dahiya Ankur Kaushal Vijai Kumar Gupta Adesh K Saini Reena V Saini Source Type: research
TRPM8 as a Potential Biomarker and Therapeutic Target for Gastric Cancer Identified by a Combination of Text Mining and RNA Sequencing
CONCLUSION: This study provides insights into the underlying role of TRPM8 in cell proliferation. In addition, TRPM8 may be used as a potential therapeutic target for patients with gastric cancer.PMID:37728085 | DOI:10.2174/1566523223666230529142423 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Na Kong Wendong Li Jun Zhang Xin Wang Lin Hu Qiqi Xu Source Type: research
MicroRNA Theranostics in Cancer
Curr Gene Ther. 2023;23(5):329. doi: 10.2174/156652322305230808102847.NO ABSTRACTPMID:37728083 | DOI:10.2174/156652322305230808102847 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Sujay Paul Source Type: research
Exosomal miRNAs as Next-generation Therapy Vehicles in Breast Cancer
Curr Gene Ther. 2023;23(5):330-342. doi: 10.2174/1566523223666230215103524.ABSTRACTThe second most pervasive cancer affecting the survival of women across the world is breast cancer. One of the biggest challenges in breast cancer treatment is the chemoresistance of cancer cells to various medications after some time. Therefore, highly specific blood-based biomarkers are required for early breast cancer diagnosis to overcome chemoresistance and improve patient survival. These days, exosomal miRNAs have attracted much attention as early diagnostic blood-based biomarkers because of their high stability, secretion from maligna...
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Priyanka Thakur Harshita Dahiya Ankur Kaushal Vijai Kumar Gupta Adesh K Saini Reena V Saini Source Type: research
TRPM8 as a Potential Biomarker and Therapeutic Target for Gastric Cancer Identified by a Combination of Text Mining and RNA Sequencing
CONCLUSION: This study provides insights into the underlying role of TRPM8 in cell proliferation. In addition, TRPM8 may be used as a potential therapeutic target for patients with gastric cancer.PMID:37728085 | DOI:10.2174/1566523223666230529142423 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Na Kong Wendong Li Jun Zhang Xin Wang Lin Hu Qiqi Xu Source Type: research
MicroRNA Theranostics in Cancer
Curr Gene Ther. 2023;23(5):329. doi: 10.2174/156652322305230808102847.NO ABSTRACTPMID:37728083 | DOI:10.2174/156652322305230808102847 (Source: Current Gene Therapy)
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Sujay Paul Source Type: research
Exosomal miRNAs as Next-generation Therapy Vehicles in Breast Cancer
Curr Gene Ther. 2023;23(5):330-342. doi: 10.2174/1566523223666230215103524.ABSTRACTThe second most pervasive cancer affecting the survival of women across the world is breast cancer. One of the biggest challenges in breast cancer treatment is the chemoresistance of cancer cells to various medications after some time. Therefore, highly specific blood-based biomarkers are required for early breast cancer diagnosis to overcome chemoresistance and improve patient survival. These days, exosomal miRNAs have attracted much attention as early diagnostic blood-based biomarkers because of their high stability, secretion from maligna...
Source: Current Gene Therapy - September 20, 2023 Category: Genetics & Stem Cells Authors: Priyanka Thakur Harshita Dahiya Ankur Kaushal Vijai Kumar Gupta Adesh K Saini Reena V Saini Source Type: research
